CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

UCB

UCBJY
$46.13BLarge Cap

Next catalyst

Phase 3Q4 2026

Bimekizumab

Chronic Plaque Psoriasis

Get an email about UCBJY's next catalysts

Track UCB (UCBJY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 5 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline

Catalyst Timeline

6 upcoming, 0 past

Phase 3Next

Bimekizumab Phase 3 Est. Readout

Q4 2026~QBimekizumab40

Primary completion for Bimekizumab trial (NCT06921850) in Hidradenitis Suppurativa

Source
Phase 3

bimekizumab Phase 3 Est. Readout

Q1 2027~QBimekizumab89

Primary completion for bimekizumab trial (NCT06506916) in Moderate to Severe Plaque Psoriasis

Source
Phase 3

Staccato alprazolam Phase 3 Est. Readout

March 2027~Staccato alprazolam350

Primary completion for Staccato alprazolam trial (NCT05077904) in Stereotypical Prolonged Seizures

Source
Phase 3

Rozanolixizumab Phase 3 Est. Readout (cosMOG)

Q2 2027~QRozanolixizumab113

Primary completion for Rozanolixizumab trial (NCT05063162) in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)

Source
Phase 3

Zilucoplan Phase 3 Est. Readout (ziMyG)

Q2 2027~QZilucoplan8

Primary completion for Zilucoplan trial (NCT06055959) in Generalized Myasthenia Gravis

Source
Phase 2

Galvokimig Phase 2 Est. Readout

Q2 2027~QGalvokimig160

Primary completion for Galvokimig trial (NCT07277660) in Atopic Dermatitis

Source

Market Overview

Stock performance and key metrics

NASDAQHealthcare🇺🇸North America9.0K employees
Drug Pipeline

CDP870

Phase 3

Arthritis, Rheumatoid

SPM 927

Phase 3

Partial Seizures With or Without Secondary Generalization

Cimzia

Phase 3

Crohn Disease

Etanercept

Phase 3

Psoriasis

Certolizumab Pegol

Phase 3

Rheumatoid Arthritis

Brivaracetam

Phase 3

Epilepsy

Secukinumab

Phase 3

Chronic Plaque Psoriasis

levocetirizine dihydrochloride

Phase 3

Rhinitis

Ketotifen

Phase 3

Rhinitis, Allergic, Perennial

Lacosamide

Phase 3

Epilepsy

Bimekizumab

Phase 3

Chronic Plaque Psoriasis

BRV

Phase 3

Unverricht-Lundborg Disease

Epratuzumab

Phase 3

Systemic Lupus Erythematosus

Brivaracetam tablets

Phase 3

Epilepsy

certolizumab pegol (CDP870, CZP)

Phase 3

Crohn Disease

Keppra XR

Phase 3

Epilepsy

Alprostadil (Prostaglandin E1)

Phase 3

Stage II Peripheral Arterial Occlusive Disease

Carbamazepine

Phase 3

Epilepsy

fenfluramine

Phase 3

Dravet Syndrome

Romosozumab

Phase 3

Osteoporosis

zilucoplan (RA101495)

Phase 3

Generalized Myasthenia Gravis

Certolizumab pegol (CZP)

Phase 3

Crohn's Disease

DZP

Phase 3

Systemic Lupus Erythematosus

Brivaracetam (BRV)

Phase 3

Epilepsy

Levetiracetam (LEV)

Phase 3

Epilepsy

Brivaracetam (ucb 34714)

Phase 3

Epilepsy

Staccato alprazolam

Phase 3

Stereotypical Prolonged Seizures

Brivaracetam oral solution

Phase 3

Childhood Absence Epilepsy

Carbamazepine Controlled Release (CBZ-CR)

Phase 3

Epilepsy

Keppra XR (Levetiracetam XR)

Phase 3

Epilepsy

Carbamazepine-Controlled Release (CBZ-CR)

Phase 3

Epilepsy

Cetirizine

Phase 3

Dermatitis

e-Device

Phase 3

Moderate and Severe Active Rheumatoid Arthritis

USL261

Phase 3

Epilepsy

Alprazolam orally disintegrating tablets

Phase 3

ANXIETY

PARCOPA

Phase 3

Parkinson's Disease

Brivaracetam Film-coated tablet

Phase 3

Childhood Absence Epilepsy

Certolizumab Pegol + Methotrexate (MTX)

Phase 3

Rheumatoid Arthritis

Kemstro

Phase 3

Multiple Sclerosis

Rozanolixizumab

Phase 3

Generalized Myasthenia Gravis

Levocetirizine

Phase 3

Rhinitis, Allergic, Seasonal

Rotigotine

Phase 3

Restless Legs Syndrome

Antiepileptic drugs with market authorization available per country

Phase 3

Epilepsy

Zilucoplan

Phase 3

Generalized Myasthenia Gravis

SPM 929

Phase 3

Painful Diabetic Neuropathy

Certolizumab Pegol (CDP870)

Phase 3

Crohn's Disease

Levetiracetam

Phase 3

Epilepsy

Carbamazepine-Controlled Release

Phase 3

Epilepsy

Keppra® extended release formulation - XR

Phase 3

Epilepsy

L-dopa

Phase 3

Idiopathic Parkinson's Disease

CZP

Phase 3

Arthritis, Psoriatic

Lasosamide Oral Solution

Phase 3

Epilepsy

SPM 962

Phase 3

Parkinson's Disease

Lacosamide Tablet

Phase 3

Epilepsy

Risankizumab

Phase 3

Psoriatic Arthritis

Rotigotine Nasal Spray

Phase 2

Restless Legs Syndrome

UCB0022

Phase 2

Parkinson Disease

Levocetirizine oral solution

Phase 2

Allergic Rhinitis

Lorazepam

Phase 2

Epilepsy

CDP323

Phase 2

Relapsing Multiple Sclerosis

UCB7665

Phase 2

Thrombocytopenia

Tocilizumab (Actemra or RoActemra)

Phase 2

Rheumatoid Arthritis

SPM927/Lacosamide

Phase 2

Painful Diabetic Neuropathy

Olokizumab

Phase 2

Rheumatoid Arthritis

doxecitine and doxribtimine

Phase 2

Thymidine Kinase 2 Deficiency

ginisortamab

Phase 2

Advanced Solid Tumors

Bepranemab

Phase 2

Alzheimer's Disease

UCB9741

Phase 2

Atopic Dermatitis

CDP6038

Phase 2

Arthritis

SPM 936

Phase 2

Idiopathic Restless Leg Syndrome

Levocetirizine drops

Phase 2

Rhinitis

UCB0942

Phase 2

Highly Drug-resistant Focal Epilepsy

Certolizumab Pegol (Cimzia®)

Phase 2

Psoriasis

Dapirolizumab pegol (DZP)

Phase 2

Systemic Lupus Erythematosus (SLE)

Somatostatin UCB (drug)

Phase 2

Peptic Ulcer

UCB1381

Phase 2

Atopic Dermatitis

Galvokimig

Phase 2

Atopic Dermatitis

Seletracetam (ucb 44212)

Phase 2

Epilepsy, Partial

Seletracetam (UCB44212)

Phase 2

Epilepsy, Partial

UCB0599

Phase 2

Early-stage Parkinson's Disease

Padsevonil

Phase 2

Drug-resistant Epilepsy

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in UCB's drug pipeline?→

CatalystAlert tracks 81 drug candidates in UCB's (UCBJY) pipeline across Phase 3, Phase 2. Its lead program is Bimekizumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is UCB's next FDA catalyst?→

UCB's (UCBJY) next tracked catalyst is a Phase 3 readout expected Q4 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track UCBJY biotech catalysts?→

Add UCBJY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow UCB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply